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ABSTRACT 
Background:  The aim of this study was to estimate the contribution of deleterious 
mutations in BRCA1, BRCA2, MLH1, MSH2, MSH6 and PMS2 to invasive epithelial 
ovarian cancer in the population. 
Methods:  The coding sequence and splice site boundaries of all six genes were 
amplified in germline DNA from 2,240 invasive EOC cases and 1,535 controls. 
Barcoded fragment libraries were sequenced using the Illumina GAII or HiSeq and 
sequence data for each subject de-multiplexed prior to interpretation.  GATK and 
Annovar were used for variant detection and annotation. After quality control 2,222 
cases (99.2 per cent) and 1,528 controls (99.5 per cent) were included in the final 
analysis.  
Results:  We identified 193 EOC cases (8.7 per cent) carrying a deleterious mutation 
in at least one gene compared to 10 controls (0.65 per cent).   Mutations were most 
frequent in BRCA1 and BRCA2, with 84 EOC cases (3.8 per cent) carrying a BRCA1 
mutation and 94 EOC cases (4.2 per cent) carrying a BRCA2 mutation.  The combined 
BRCA1 and BRCA2 mutation prevalence was 11 per cent in high-grade serous disease.  
Seventeen EOC cases carried a mutation in a mismatch repair gene, including 10 
MSH6 mutation carriers (0.45 per cent) and 4 MSH2 mutation carriers (0.18 per cent).  
Conclusions: At least one in ten women with high-grade serous EOC has a BRCA1 or 
BRCA2 mutation. The development of next generation sequencing technologies 
enables rapid mutation screening for multiple susceptibility genes at once, suggesting 
that routine clinical testing of all incidence cases should be considered. 
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Introduction 
Epithelial ovarian cancer (EOC) is the most fatal gynaecological malignancy, 
resulting in approximately 140,000 deaths worldwide per year (1).  Despite some 
recent advances in treatment, there have been only slight improvements in survival in 
patients diagnosed with EOC in over four decades.  Approximately 70 per cent of 
EOC cases are diagnosed with advanced stage disease, in whom five-year survival is 
less than 30 per cent.  By contrast, survival is over 90 per cent for patients with Stage 
I disease (2). Prophylactic salpingo-oophorectomy reduces the risk of 
ovarian/fallopian tube cancer in carriers of high-penetrance alleles of BRCA1 or 
BRCA2 by 75 - 96 per cent (3,4).  
Individual susceptibility to EOC has a substantial inherited genetic component - 
women with a single-first degree relative with ovarian cancer have a 3-fold greater 
risk of developing the disease than women without a family history (5).  The known 
ovarian cancer susceptibility genes, which include BRCA1 and BRCA2, are estimated 
to explain less than 40 per cent of the excess familial risk of ovarian cancer.  Genes 
other than BRCA1 and BRCA2 that confer >20 fold lifetime risk of EOC are unlikely 
to exist, given that BRCA1 and BRCA2 explain most multi-generation, multi-case 
EOC families (6,7).  
Common, low penetrance susceptibility alleles also contribute to familial EOC risk, 
and genome wide association studies (GWAS) performed in large-scale, case-control 
studies with sample sizes in excess of 40,000 subjects have so far identified eleven 
confirmed ovarian cancer susceptibility alleles, each conferring relative risks of less 
than 1.5 (8-14).  However, in combination, these alleles account for just 4 per cent of 
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the excess familial ovarian cancer risk (13) suggesting other susceptibility alleles are 
likely to exist.  A wide variety of genetic models have been suggested to account for 
the “missing heritability” including the possibility that there are several rare alleles 
that confer relative risks greater than 3. Evidence for this has emerged through the 
recent identification of deleterious alleles in RAD51C, RAD51D and BRIP1 that are 
associated with an increased risk of EOC (15-17).  Truncating mutations in the DNA 
mismatch repair genes are also associated with modest risks of EOC (18,19).  In 
particular mutations of MLH1, MSH2, MSH6 and PMS2 are reported to be associated 
with ovarian cancer as part of the Lynch Syndrome (18,20,21). 
Many studies have investigated the contribution of BRCA1 and/or BRCA2 to EOC 
incidence in the population but most of these have involved fewer than 500 subjects 
(22).  Only two studies have reported BRCA1 and BRCA2 mutation prevalence based 
on more than 1000 samples (23,24).  Mutation prevalence reported in population-
based studies that screened the full coding sequence varies widely from 3.4 per cent to 
9.8 per cent for BRCA1 and from 0.6 per cent to 5.7 per cent for BRCA2 (22).  A 
handful of studies have reported the prevalence of deleterious mutations in the MMR 
genes to be 0.5-3 per cent in EOC (21,25-28). Furthermore, no large studies have 
evaluated the frequency of deleterious mutations in these genes in non-cancer 
controls.  The aim of this study was to establish the contribution of predicted 
deleterious mutations in the BRCA1, BRCA2, MLH1, MSH2, MSH6 and PMS2 to 
ovarian cancer risk in the population using targeted next generation sequencing in two 
large case-control studies.  
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Results 
Sequence data for BRCA1 BRCA2, MLH1, MSH2, MSH6 and PMS2 were available in 
2,222 cases and 1,528 controls after quality control.  The clinical-pathological 
characteristics of cases in this study are presented in Table 1. Controls were 
individuals with no known diagnosis of ovarian or any other cancer. 
We detected a total of 813 different variants of which 85 (10 per cent) were frameshift 
indels, 10 (1.2 per cent) were variants predicted by MaxEntScan (29) to affect gene 
splicing, 37 (4.6 per cent) were nonsense substitutions and 506 (62 per cent) were 
missense substitutions and 175 (22 percent) were synonymous substitutions. Of the 
missense substitutions, 24 had an alternate allele frequency greater than 2 per cent and 
were not considered deleterious.  We classified six rare missense variants in BRCA1 
as deleterious, two in BRCA2, one in MLH1 and two in MSH6.  Three hundred and 
forty missense variants were predicted by SIFT/polyphen-2 to be neutral and 131 
were predicted to have some functional effect.  These were all considered 
unclassified.  One nonsense substitution – BRCA2 K3326X – had a carrier frequency 
of 2.0 per cent in controls and 2.5 per cent in the cases (P=0.31), and so was not 
considered deleterious.  
Two hundred and three subjects carried at least one of the 143 different deleterious 
variants (henceforth mutations) identified. The mutation prevalence was 8.7 per cent 
in cases (193 out of 2,222) and 0.65 per cent in controls (10 out of 1,528).  Details of 
each protein truncating mutation and potential deleterious missense/synonymous 
mutation we identified are given in Supplementary Table S1 and Supplementary 
Table S2, respectively.  In EOC cases, we identified 84 BRCA1 mutation carriers (3.8 
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per cent), 94 BRCA2 mutation carriers (4.2 per cent), 10 MSH6 mutation carriers (0.45 
per cent), 4 MSH2 mutation carriers (0.2 per cent), and 2 MLH1 mutation carriers (0.1 
per cent) and 1 PMS2 mutation carrier (0.05 per cent) (Table 2).  One case with a 
mucinous subtype ovarian cancer had a deleterious mutation in both MSH6 and 
BRCA1; another case with a clear cell subtype ovarian cancer had a deleterious 
mutation in both BRCA1 and MLH1.  Of the deleterious mutations in controls, we 
identified one deleterious mutation in BRCA1, 4 in BRCA2, 2 in MLH1 and 3 in 
MSH6 (Table 2).  
Thirty-one deleterious mutations were detected in more than one individual, with the 
most common, 4065_4068delTTGA in BRCA1, being found in seven individuals.  
The BRCA1 mutation 5266dupC (known as 5382insC), which is relatively common in 
individuals of Eastern European origin, was identified in 5 individuals.  Of the total 
195 deleterious mutations in cases, 127 (65 per cent) were insertion or deletion 
frameshifts, 41 (21 per cent) were nonsense substitutions, 12 (6.2 per cent) were 
variants situated near exon/intron boundary that were predicted to affect gene 
splicing, and 15 (7.7 per cent) were previously reported pathogenic/likely pathogenic 
missense substitutions (30-33) (Supplementary Table S2).  In controls, 4 mutations 
were frameshift indels, 4 were nonsense mutations and 2 variants that were predicted 
to affect splicing.   
Previous studies have indicated that mutations located in specific regions of BRCA1 
(cDNA 2282-4066) (7,34) and BRCA2 (cDNA 2807-6401, termed the Ovarian Cancer 
Cluster Region or OCCR) (7,35) are associated with a relatively higher risk of ovarian 
cancer compared to breast cancer.  In our study, the proportion of BRCA1 mutations 
located in this region was similar to that would be expected by chance if mutations 
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occurred evenly cross the coding region (33 per cent vs 32 per cent).  The proportion 
of mutations in the OCCR region of BRCA2 was significantly higher than that 
expected by chance (54 per cent vs 35 per cent, P=0.0017). 
We compared the frequency of deleterious mutation carriers in cases and controls 
using an odds ratio.  The odds ratio was 60 (95% confidence interval 10 - 2100) for 
BRCA1, 17 (6.3 - 63) for BRCA2 and 2.3 (0.83 – 8.2) for MMR gene mutation 
carriers.  The average cumulative risks of ovarian cancer by age 80 years are 
estimated to be 61 per cent (15 – 99 per cent) for BRCA1, 24 per cent (10 – 62 per 
cent) for BRCA2 and 3.7 per cent (1.4 – 13 per cent) for MMR genes. 
Associations with clinical and histopathological characteristics of ovarian cancer:  
BRCA1 mutation carriers were diagnosed at a median age of 52 years (range 33-82 
years); this compared to 57 years (range 33 – 84 years) for BRCA2 carriers, 54 years 
(range 43-73 years) for MMR gene mutation carriers and 59 years (range 19 -91) for 
non-mutation carriers (Table 3).  The proportion of cases of the serous subtype was 
higher in the Mayo Clinic case-series (74 per cent) than the SEARCH case-series (46 
per cent) (Table 1).  Of these, 34 per cent of SEARCH cases (N=451) and 72 per cent 
of Mayo Clinic cases (N=654) were classified as high-grade serous subtype. There are 
two primary reasons for this: first, the SEARCH cases had 16 per cent unspecified 
subtype derived from routine pathology report, whereas the Mayo Clinic cases all had 
central pathology review and only 5 per cent were unspecified; second, SEARCH 
included prevalent cases and so the proportion of good prognosis tumours (non-
serous) will be higher. In total, 57 per cent of the cases were diagnosed with serous 
tumours; the remainder were a mix of endometrioid, clear cell, mucinous or 
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other/unknown subtypes (Table 1).  The prevalence of deleterious mutations varied by 
histopathological subtype and by study (Table 2).  In the combined results, 122 of the 
178 BRCA1 and BRCA2 mutation carriers (69 per cent) were identified in patients 
diagnosed high-grade serous EOC, and BRCA1/BRCA2 mutation prevalence in high-
grade serous disease was 11 per cent compared to 5 per cent for other subtypes.   A 
total of 17 MMR gene mutations were identified.  Five EOC cases with MMR gene 
mutations were clear cell tumours, three were undifferentiated tumours, four were 
high-grade endometrioid tumours, two were high-grade serous tumours and one each 
of low-grade serous, low-grade-endometrioid and high-grade-mucinous tumour.  
Information on breast and/or ovarian cancer history in first-degree relatives was 
available for 1,862 of 2,222 cases.  A family history of breast cancer only was 
reported by 302 cases, 88 reported a family history of ovarian cancer only and 18 
reported a family history of both breast and ovarian cancer.  Of the 408 cases 
reporting a family history, 78 (19 per cent) carried a deleterious variant in either 
BRCA1 or BRCA2 compared to 70 mutation carriers out of 1,454 cases (4.8 per cent) 
with no family history (Table 4).  Information on family history was available for 11 
of the 17 MMR gene mutation carriers; five of these women reported a first- or 
second-degree relative with endometrial cancer and three reported a first- or second-
degree relative with colorectal cancer. 
Association between rare missense variants and ovarian cancer risk 
In addition to the probable deleterious variants, we identified 471 unclassified 
missense variants across all six genes of which 131 are predicted to have a functional 
effect based on SIFT and polyphen-2.  We compared the relative burden of the 
 9 
possibly functional variants in cases and controls for each gene using the rare 
admixture maximum likelihood test (RAML) (36).  We found little evidence for 
association of rare missense variation in any of these genes and ovarian cancer risk 
(all p > 0.05). 
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Discussion 
This is the largest population-based ovarian cancer study to estimate the prevalence of 
mutations in BRCA1, BRCA2 and the MMR genes reported to date.  Overall, 8.7 per 
cent of epithelial ovarian cancer cases had a mutation in one of the six genes 
compared with 0.65 per cent in controls.  We have almost certainly underestimated 
the true mutation prevalence in this series of genes, as some deleterious mutations will 
have been missed using our next generation sequencing approach.  For example, we 
did not sequence the entire coding sequence in all individuals; the mean coverage for 
the targeted gene regions was 84 per cent ranging from 71 per cent- 92 per cent for the 
six genes at read depth at least 15 (Supplementary Table 3).  In addition, some 
missense substitutions of uncertain significance, which were excluded from the 
prevalence estimates, may be true deleterious mutations.  Finally, our PCR based 
method would not have been able to detect large genomic rearrangements, which we 
have previously shown account for ~10 per cent of mutations in BRCA1/BRCA2 (7) 
and 5 to 20 per cent of all MMR gene mutations in Lynch syndrome families (37,38).  
By extrapolation, we calculate that this study may have underestimated the true 
prevalence of deleterious BRCA1, BRCA2 and MSH6 mutations by about 17, 24 and 
30 per cent respectively which would increase the deleterious mutation prevalence 
estimates in EOC to 4.6 per cent for BRCA1, 5.6 per cent for BRCA2 and 0.6 per cent 
for MSH6.   
BRCA1 or BRCA2 mutations were more common in the high-grade serous ovarian 
cancer subtype.  This is consistent with the previous findings that DNA double strand 
break repair is associated with high-grade serous EOC (39).  The estimated true 
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prevalence of BRCA1 and BRCA2 in high-grade serous ovarian cancer is 14.1 per 
cent: this is consistent with The Cancer Genome Atlas (TCGA) project, which 
identified germline BRCA1/BRCA2 in 16 per cent of high-grade serous EOC cases 
(40).   
The frequency of mutations in MSH6 for EOC cases (10/2222 or 0.45 per cent) is 
similar to that reported by Walsh et al (2/360 or 0.55 per cent) (28).  Similar to this 
study, and as previously reported for epithelial ovarian cancer cases in Lynch 
syndrome families (20), mutations in MMR genes were mostly of the non-serous 
subtype.  
The frequency of mutations in BRCA1 and BRCA2 is somewhat lower than that 
reported in the two previously largest published studies (8 per cent in SEARCH, 8 per 
cent in Mayo Clinic cases, 13 per cent in Zhang et al (23) and 14 per cent in Alsop et 
al.(24)).   However, the published data include data for large genomic rearrangements.  
In addition the ancestry of the populations is different - the three variants common in 
the Ashkenazi Jewish population accounted for 11 to 14 per cent of all deleterious 
variants identified in the two large published case series compared to 3 per cent in our 
study (Supplementary Table 4).  The deleterious variant prevalence in the high grade 
serous subtype was substantially higher in the Australian cases series (23 per cent) 
than in SEARCH (14 per cent), Mayo Clinic cases (9 per cent) or the Canadian case 
series (18 per cent).  The clinical characteristics of the four case series are broadly 
similar apart from a smaller proportion of serous cases in SEARCH and a higher 
proportion of cases diagnosed at age 60 or older in Mayo Clinic cases (Supplementary 
Table 5).  Thus, reasons for this difference are not clear. 
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In summary, we estimate that BRCA1 and BRCA2 together are major contributors to 
at least one in every 12 invasive EOC cases, and one in every 10 high-grade serous 
EOC cases.  Mutations in MMR genes are responsible for at least one in every 131 
EOC cases.  The recently published NICE Guideline for the management of women 
with a family history of breast cancer has recommended that individuals with a 10 per 
cent or greater probability of carrying a deleterious mutation in BRCA1 or BRCA2 
should be offered genetic testing (NICE clinical guidelines Issued: June 2013, 
CG164).  Thus, all women with high-grade serous ovarian would be eligible for 
BRCA1 and BRCA2 testing under the NICE Guideline.  Given that PARP inhibitors 
have been shown to improve progression-free survival among patient with platinum-
sensitive, relapsed, high-grade serous ovarian cancer (41), such testing may have 
important implications for the patient.  The potential implications for the family of 
BRCA1 or BRCA2 mutation carriers are clearer, as cascade testing of unaffected 
female relatives will identify unaffected carriers for whom the benefits of prophylactic 
salpingo-oophorectomy in reducing risk of incident ovarian, fallopian tube and 
peritoneal cancer are well established.  Furthermore, it will be feasible to use a 
targeted sequencing approach for clinical testing of multiple genes in a single assay to 
replace the conventional clinical genetic testing which was done gene by gene with 
relatively high cost.  The widespread application of panel sequencing in unselected 
women in the UK population and the provision of prophylactic salpingo-
oophorectomy to mutation carriers has the potential to reduce the incidence of 
epithelial ovarian cancer by 8 per cent. 
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Materials and Methods 
Study subjects 
Confirmed invasive EOC cases and unaffected controls were from two case-controls 
studies: the population based SEARCH study (1321 cases/1389 controls) from the 
United Kingdom, and the hospital-based Mayo clinic study (919 cases/146 controls) 
from the USA.  The studies have been previously described (42). Briefly, the 
SEARCH ovarian cancer study comprises 1321 invasive epithelial ovarian cancer 
cases <75 years from East Anglian West Midlands & Trent regions of England. 
Prevalent cases diagnosed between 1991-1998; incident cases diagnosed 1998 
onwards.  All eligible cases were identified through Cancer Registry.  Pathology 
information was abstracted from routine pathology reports.  Cancer free controls are 
from a population based controls series from East Anglia (UK) and frequency 
matched to cases on age.  The Mayo Clinic ovarian cancer study comprises 919 cases 
diagnosed from 2000 onwards at Mayo Clinic, for whom a diagnosis of histologically-
confirmed primary epithelial ovarian cancer was ascertained within one year of 
consent.  The pathology of all eligible cases were centrally reviewed by a group of 
gynecologic pathologists.  Controls were frequency matched to cases on race and age 
from the same study area.  Based on data from single nucleotide polymorphism 
genotyping, 2,214 cases and 1,518 controls were of European ancestry (13).  For 
quality control purposes we also included 43 duplicate samples and 34 positive 
controls known to be BRCA1 or BRCA2 mutation carriers.  Both studies have ethics 
committee approval, and all study subjects provided written, informed consent.   
Sequencing library preparation and sequencing 
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We used the 48.48 Fluidigm Access Arrays™ for target sequence enrichment.  This 
method uses a 4-primer chemistry that allows the addition of barcode and adapter 
sequences to small target regions (<210bp) during up to 10-plex PCR amplification.  
A total of 338 primer-pairs were designed to cover the exons and splice sites of 
BRCA1, BRCA2, MLH1, MSH2, MSH6 and PMS2 (Supplementary Table S3).  The 
combined sequencing target for these six genes was about 28kb with some of the 
sequence being covered by multiple amplicons.  The primer design achieved more 
than 94 per cent coverage of the coding exons and potential splice site (i.e. 20 bp in 
the intron for 3’ acceptor sites and 6 bp in the intron for donor 5’ sites) sequence for 
each gene.  Sequencing library preparation used 1.25µl germline DNA at 75ng/µl 
according to the manufacturer’s protocol (Fluidigm, San Francisco, CA, US).  
Sequencing libraries were quantified using a KAPA library quantification kits with 
specific probes for the ends of the adapters according to the manufacturer’s protocol 
(Kapabiosystems, Boston, MA, US).  The sequence library was sequenced using 
either the single end sequencing on the Illumina GAII (1,443 samples) or paired end 
sequencing on the Illumina HiScan (2,332 samples) according to the manufacturer’s 
protocol (Illumina Inc, San Diego, CA, US).  Sample barcoding enabled 384 
individual’s sample to be sequenced on each lane of the sequencer. 
Data analysis 
Sequenced reads were de-multiplexed using standard Illumina software. We used the 
Burrows-Wheeler Aligner (BWA) (43) for sequencing read alignment against the 
human genome reference sequence (GRCh37, UCSC hg19).  The Genome Analysis 
Toolkit (GATK) (44) was then used for base quality-score recalibration, local 
insertion/deletion (indel) realignment, substitution and indel discovery.  Variants 
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were only considered if they satisfied the set of recommended GATK filters, as 
described in the GATK best practices guide. ANNOVAR (45) was used to annotate 
the sequence variation detected.  We used PolyPhen-2 (46) and SIFT (47) to predict 
the function of missense variants.  We used MaxEntScan (29) to predict the 
pathogenic potential of putative splicing mutations in sequences from 3 bp in the exon 
to 20 bp in the intron for 3’ acceptor sites and 3 bp in the exon and 6 bp in the intron 
for the donor 5’ sites.  MaxEntScan provides a score for the strength of the splice site 
and enables the scores for the consensus and variant sequences to be compared.  It has 
been suggested that a score for a variant sequence 20 per cent lower than the 
consensus sequence score as likely to result in abnormal splicing (48).  However, after 
applying this criterion we classified multiple splice site variants as deleterious in both 
cases and controls. We therefore applied a more stringent criterion of 40 per cent 
lower, which identified 17 variants, 16 of these occurring in cases. 
Variant alternate allele frequency was defined as the fraction of alternative allele 
reads compared to the total number of reads at the variant locus.  We used the variants 
called in the sequence data from the 43 duplicate samples and additionally the BRCA1 
and BRCA2 positive controls to define thresholds, based on coverage and alternate 
allele frequency, for definitive variant calling in the full data set.  Variants with depth 
< 15 were not called.  Alternate allele heterozygotes were called if (1) depth ≥500 and 
alternative allele frequency ≥10 per cent; (2) 250 ≤ depth <500 and alternative allele 
frequency ≥15 per cent; (3) 30 ≤ depth <250 and alternative allele frequency ≥20 per 
cent; (4) 15 ≤ depth <30 and alternative allele frequency ≥30 per cent.  Samples with 
fewer than 80 per cent of amplicons covered at a read depth of ≥ 15 were excluded 
from subsequent analyses (a total of 7 controls and 18 cases failed in both sequencing 
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runs). We defined deleterious variants as those that are predicted to result in protein 
truncation (frame shift indels, consensus splice site substitutions and nonsense 
substitutions) or those missense mutations that have been previously reported or 
classified (e.g http://www.insight-group.org/ for MMR missense variants 
classification)  or predicated by MaxEntScan as deleterious.   
The median read depth for our targeted sequencing was 102 (IQR 91– 115) and 548 
(IQR 492-626) for Illumina GAII and HiSeq, respectively.  Eighty-two per cent of 
targeted sequence base had read depth ≥30 and 85 per cent had read depth ≥15.  The 
average sequencing coverage for these six genes is summarized in Supplementary 
Table S3.  The concordance rate for the 43 duplicates was 100 per cent.  Thirty-one of 
34 (91 per cent) known BRCA1 or BRCA2 positive controls were called correctly.  
Three mutations were missed because the read depth of the relevant amplicon was less 
than 15.  
Mutation validation 
Two hundred and five potentially deleterious variants were identified.  We inspected 
the sequence alignments for all the deleterious variants using the Integrative Genomic 
viewer (IGV) (49).  Ninety-four per cent (193/205) of these had an alternative allele 
read frequency ≥30 per cent. We validated 24 deleterious variants, including all 
variants with an alternative allele read frequency of less than 30 per cent (n=12) by 
PCR amplification and Sanger sequencing. 
Unclassified variant analysis 
We also identified multiple unclassified, but putative functional missense variants 
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with allele frequencies of less than two per cent in the samples.  Because the statistical 
power to detect single rare alleles by association, even with large sample sizes is 
modest, we performed burden tests, which combines the information across multiple 
variants to increase statistical power.  We classified variants with frequency ≤2 per 
cent into three groups:  (1) deleterious variants as defined previously; (2) variants 
predicted to have a damaging effect on protein function - SIFT score <0.05 and 
polyphen-2 classified as possibly damaging/probably damaging; (3) variants with 
probable benign effects.  We used the RAML (36) to test for the association of 
uncommon missense variants (MAF≤ 2 per cent) with ovarian cancer risks on a gene-
by-gene basis.  RAML takes account of variants that increase or decrease risk. Only 
subjects with a call rate greater than 80 per cent and variants with a call rate greater 
than 80 per cent with genotype frequencies consistent with Hardy-Weinberg 
equilibrium (P>10-5) were included in these analyses. 
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Table 1. Characteristics of the ovarian cancer subjects (N = 2,222) 
 SEARCH       
(N = 1310) 
Mayo Clinic       
(N= 912) 
Total (N) 
Mean age at diagnosis, years 
(range) 
55.9 (19-74) 62.5 (23-91) 58.6 (19-91) 
Morphology    
   Serous 600 (46%) 677 (74%) 1277 (57%) 
   Endometrioid 212 (16%) 110 (12%) 322 (14%) 
   Clear Cell 137 (10%) 55 (6.0%) 192 (8.6%) 
   Mucinous 132 (10%) 25 (3.0%) 157 (7.1%) 
   Other/Unknown 229 (16%) 45 (5.0%) 274 (12%) 
Stage     
   I 431 (33%) 141 (15%)  572 (26%) 
   II 121 (9%) 51 (5.6%) 172 (7.7%) 
   III 368 (28%) 538 (59%) 1143 (51%) 
   IV 66 (5.0%) 171 (19%) 237 (11%) 
   Unknown 324 (25%) 11 (1.2%) 335 (15%) 
Grade    
   Low grade 169 (13%) 128 (14%) 297 (13%) 
   High grade 714 (55%) 754 (83%) 1468 (66%) 
   Unknown 427 (33%) 30 (3%) 457 (21%) 
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Table 2.  Number of mutations identified in 6 genes by histology subtype   
 
Control 
(n=1528) SEARCH cases (n=1310) Mayo Clinic cases (n=912) Cases combined (n=2222) 
 
n % High-grade 
serous 
% Other  % High-grade 
serous 
% Other  % High-grade 
serous 
% Other  % 
Non-carrier 1518 99.4 388 86 803 93.5 593 91 245 95 981 89 1,048 94 
Mutation carrier               
Any 10 0.6 63 14 56 6.5 61 9.3 13 5 124 11 69 6 
BRCA1 1 0.07 25 5.5 19 2.2 33 5.1 7 2.7 58 5.3 26 2.3 
BRCA2 4 0.3 38 8.4 26 3.0 26 4.0 4 1.6 64 5.8 30 2.7 
MMR* 5 0.3 0 0 13 1.5 2 0.3 2 0.78 2 0.18 15 1.3 
Total 1,528 100 451 100 859 100 654 100 258 100 1,105 100 1,117 100 
*one case had both BRCA1 and MLH1 mutation and another case had both BRCA1 and MSH6 mutation. 
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 Table 3.  Mutation status by age of disease onset  
Age at diagnosis (n, %) Mutation status 
< 40yrs 40-49 yrs 50-59yrs ≥ 60yrs 
Non-carrier (n= 2029) 94 (5) 286 (14) 648 (32) 1,001 (49) 
Mutation carrier (n= 193) 6 (3) 50 (27) 76 (39) 61 (31) 
 BRCA1 4 (5) 29 (35) 28 (33) 23 (27) 
 BRCA2 2 (2) 16 (17) 42(45) 34 (36) 
 MLH1/MSH2/MSH6/PMS2* 0 (0) 6 (35) 6 (35) 5 (29) 
*one case had both BRCA1 and MLH1 mutation and another case had both BRCA1 
and MSH6 mutation. 
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Table 4.  Mutation status by 1st degree of family history of ovarian/breast cancer 
in ovarian cancer cases   
With FH (n=408) Gene Without FH 
(n= 1454) 
% 
OvFH1 % BrFH2 % OvBrFH3 % 
Non-carrier 1374 94 63 72 251 83 12 67 
Mutation carrier 80 5.5 25 26 51 16 6 33 
 BRCA1 37 2.5 13 15 19 6.3 5 28 
 BRCA2 33 2.3 10 11 30 10 1 5.6 
 MLH1* 2 0.14 0 0 0 0 0 0 
 MSH2 2 0.14 0 0 1 0.33 0 0 
 MSH6* 7 0.48 2 2.3 1 0.33 0 0 
 PMS2 1 0.07 0 0 0 0 0 0 
1 OvFH: ovarian cancer family history only;  2 BrFH: breast cancer family history only; 3 OvBrFH: both 
ovarian and breast cancer family history.  *one case had both BRCA1 and MLH1 mutation and another 
case had both BRCA1 and MSH6 mutation.  
 
 
 
Supplementary Table S1: Catalogue of protein truncating mutations found in 
the study 
Status Gene Exon cDNA Protein MutationType Refage Morphology 
control BRCA1 8 c.520delC p.Q174fs fs del 62 NA 
control BRCA2 11 c.3158T>G p.L1053* nonsense 54 NA 
control BRCA2 11 c.2330dupA p.D777fs fs ins 55 NA 
control BRCA2 8 c.658_659delGT p.V220fs fs del 55 NA 
control BRCA2 3 c.145G>T p.E49* nonsense 52 NA 
control MLH1 18 c.2080G>T p.E694* nonsense 59 NA 
control MLH1 12 c.1333C>T p.Q445* nonsense 37 NA 
control MSH6 4 c.1629_1630delAA p.K543fs fs del 48 NA 
case BRCA1 2 c.34C>T p.Q12* nonsense 50 clear cell 
case BRCA1 I_5 c.213-11T>G - splicing 57 serous 
case BRCA1 7 c.427G>T p.E143* nonsense 50 serous 
case BRCA1 7 c.427G>T p.E143* nonsense 56 serous 
case BRCA1 7 c.427G>T p.E143* nonsense 43 serous 
case BRCA1 7 c.427G>T p.E143* nonsense 33 undifferentiated 
case BRCA1 I_7 c.442-3_442-3delT - splicing 62 serous 
case BRCA1 I_10 c.670+1G>A - splicing 63 serous 
case BRCA1 11 c.823_824insTA p.G275fs fs ins 82 clear cell 
case BRCA1 11 c.843_846delCTCA p.S281fs fs del 51 serous 
case BRCA1 11 c.843_846delCTCA p.S281fs fs del 49 serous 
case BRCA1 11 c.929delA p.Q310fs fs del 35 serous 
case BRCA1 11 c.929delA p.Q310fs fs del 51 undifferentiated 
case BRCA1 11 c.929delA p.Q310fs fs del 62 serous 
case BRCA1 11 c.1039_1040delCT p.L347fs fs del 44 serous 
case BRCA1 11 c.1374delC p.D458fs fs del 62 clear cell 
case BRCA1 11 c.1504_1508delTTAAA p.L502fs fs del 44 serous 
case BRCA1 11 c.1512dupT p.K505fs nonsense 40 serous 
case BRCA1 11 c.1556delA p.K519fs fs del 52 serous 
case BRCA1 11 c.1687C>T p.Q563* nonsense 48 serous 
case BRCA1 11 c.1823_1826delAGAA p.K608fs fs del 57 serous 
case BRCA1 11 c.1961dupA p.K654fs fs ins 55 serous 
case BRCA1 11 c.1961dupA p.K654fs fs ins 55 serous 
case BRCA1 11 c.2035A>T p.K679* nonsense 46 serous 
case BRCA1 11 c.2071delA p.R691fs fs del 55 serous 
case BRCA1 11 c.2071delA p.R691fs fs del 53 endometrioid 
case BRCA1 11 c.2071delA p.R691fs fs del 43 serous 
case BRCA1 11 c.2188G>T p.E730* nonsense 42 endometrioid 
case BRCA1 11 c.2188G>T p.E730* nonsense 64 mixed cell 
case BRCA1 11 c.2217dupA p.V740fs fs ins 41 serous 
case BRCA1 11 c.2457delC p.S819fs fs del 61 serous 
case BRCA1 11 c.2475delC p.D825fs fs del 57 serous 
case BRCA1 11 c.2678delA p.K893fs fs del 43 mucinous 
case BRCA1 11 c.2681_2682delAA p.K894fs fs del 47 endometrioid 
case BRCA1 11 c.2681_2682delAA p.K894fs fs del 55 undifferentiated 
case BRCA1 11 c.2681_2682delAA p.K894fs fs del 65 serous 
case BRCA1 11 c.2761C>T p.Q921* nonsense 54 serous 
case BRCA1 11 c.2857dupT p.C953fs fs ins 47 serous 
case BRCA1 11 c.2940delA p.I980fs fs del 52 serous 
case BRCA1 11 c.2989_2990dupAA p.N997fs fs ins 45 serous 
case BRCA1 11 c.3005delA p.N1002fs fs del 59 undifferentiated 
case BRCA1 11 c.3048_3052dupTGAGA p.N1018fs fs ins 56 serous 
case BRCA1 11 c.3205delC p.Q1069fs fs del 46 serous 
case BRCA1 11 c.3254_3255dupGA p.L1086fs fs ins 67 serous 
case BRCA1 11 c.3331_3334delCAAG p.Q1111fs fs del 66 serous 
case BRCA1 11 c.3627dupA p.E1210fs fs ins 46 serous 
case BRCA1 11 c.3748G>T p.E1250* nonsense 56 serous 
case BRCA1 11 c.3756_3759delGTCT p.L1252fs fs del 48 serous 
case BRCA1 11 c.3756_3759delGTCT p.L1252fs fs del 45 mixed cell 
case BRCA1 11 c.3817C>T p.Q1273* nonsense 69 serous 
case BRCA1 11 c.4035delA p.E1345fs fs del 75 serous 
case BRCA1 11 c.4065_4068delTCAA p.N1355fs fs del 36 serous 
case BRCA1 11 c.4065_4068delTCAA p.N1355fs fs del 45 serous 
case BRCA1 11 c.4065_4068delTCAA p.N1355fs fs del 58 undifferentiated 
case BRCA1 11 c.4065_4068delTCAA p.N1355fs fs del 65 serous 
case BRCA1 11 c.4065_4068delTCAA p.N1355fs fs del 66 serous 
case BRCA1 11 c.4065_4068delTCAA p.N1355fs fs del 49 serous 
case BRCA1 11 c.4065_4068delTCAA p.N1355fs fs del 59 undifferentiated 
case BRCA1 I_11 c.4096+3A>G - splicing 58 serous 
case BRCA1 12 c.4165_4166delAG p.S1389fs fs del 44 serous 
case BRCA1 12 c.4183C>T p.Q1395* nonsense 46 serous 
case BRCA1 15 c.4574_4575delAA p.Q1525fs fs del 39 undifferentiated 
case BRCA1 I_18 c.5152+5G>T - splicing 64 undifferentiated 
case BRCA1 19 c.5153G>A p.W1718* nonsense 50 mixed cell 
case BRCA1 19 c.5177_5180delGAAA p.R1726fs fs del 65 serous 
case BRCA1 20 c.5266dupC p.Q1756fs fs ins 46 serous 
case BRCA1 20 c.5266dupC p.Q1756fs fs ins 57 serous 
case BRCA1 20 c.5266dupC p.Q1756fs fs ins 64 serous 
case BRCA1 20 c.5266dupC p.Q1756fs fs ins 50 serous 
case BRCA1 20 c.5266dupC p.Q1756fs fs ins 46 serous 
case BRCA1 24 c.5503C>T p.R1835* nonsense 44 undifferentiated 
case BRCA1 24 c.5503C>T p.R1835* nonsense 54 mixed cell 
case BRCA1 24 c.5558dupA p.Y1853fs nonsense 52 serous 
case BRCA2 2 c.22_23delAG p.R8fs fs del 47 undifferentiated 
case BRCA2 4 c.379delG p.A127fs fs del 33 serous 
case BRCA2 I_6 c.517-2A>G - splicing 58 undifferentiated 
case BRCA2 8 c.658_659delGT p.V220fs fs del 62 serous 
case BRCA2 9 c.754_757delGACA p.D252fs fs del 58 clear cell 
case BRCA2 10 c.1029delA p.K343fs fs del 62 Other 
case BRCA2 10 c.1029delA p.K343fs fs del 38 serous 
case BRCA2 10 c.1265delA p.N422fs fs del 56 undifferentiated 
case BRCA2 10 c.1875_1876delTT p.F625fs fs del 84 serous 
case BRCA2 11 c.2330dupA p.D777fs fs ins 59 serous 
case BRCA2 11 c.2588dupA p.N863fs fs ins 63 serous 
case BRCA2 11 c.2808_2811delACAA p.K936fs fs del 55 serous 
case BRCA2 11 c.2808_2811delACAA p.K936fs fs del 45 endometrioid 
case BRCA2 11 c.2808_2811delACAA p.K936fs fs del 66 serous 
case BRCA2 11 c.2899_2900delCT p.L967fs fs del 52 serous 
case BRCA2 11 c.3070_3071delAT p.I1024fs fs del 68 serous 
case BRCA2 11 c.3405C>A p.Y1135* nonsense 50 endometrioid 
case BRCA2 11 c.3599_3600delGT p.C1200fs fs del 47 serous 
case BRCA2 11 c.3599_3600delGT p.C1200fs fs del 73 serous 
case BRCA2 11 c.3599_3600delGT p.C1200fs fs del 51 endometrioid 
case BRCA2 11 c.3680_3681delTG p.L1227fs fs del 53 endometrioid 
case BRCA2 11 c.3689delC p.S1230fs fs del 48 endometrioid 
case BRCA2 11 c.3785C>G p.S1262* nonsense 64 endometrioid 
case BRCA2 11 c.3847_3848delGT p.V1283fs fs del 81 serous 
case BRCA2 11 c.3847_3848delGT p.V1283fs fs del 48 serous 
case BRCA2 11 c.3865_3868delAAAT p.K1289fs fs del 53 serous 
case BRCA2 11 c.3873delA p.Q1291fs fs del 67 endometrioid 
case BRCA2 11 c.4154C>G p.S1385* nonsense 60 serous 
case BRCA2 11 c.4211_4215delCAAAT p.S1404fs fs del 63 serous 
case BRCA2 11 c.4284dupT p.F1428fs fs ins 58 serous 
case BRCA2 11 c.4284dupT p.F1428fs fs ins 50 serous 
case BRCA2 11 c.4398_4402delACATT p.L1466fs fs del 66 serous 
case BRCA2 11 c.4472_4475delTGAA p.L1491fs fs del 54 serous 
case BRCA2 11 c.4477_4480delGAAA p.E1493fs fs del 52 serous 
case BRCA2 11 c.4477_4480delGAAA p.E1493fs fs del 49 serous 
case BRCA2 11 c.4477_4480delGAAA p.E1493fs fs del 58 undifferentiated 
case BRCA2 11 c.4477_4480delGAAA p.E1493fs fs del 49 serous 
case BRCA2 11 c.4477_4480delGAAA p.E1493fs fs del 47 serous 
case BRCA2 11 c.4477_4480delGAAA p.E1493fs fs del 52 endometrioid 
case BRCA2 11 c.4576dupA p.T1526fs fs ins 64 serous 
case BRCA2 11 c.4631dupA p.N1544fs fs ins 51 serous 
case BRCA2 11 c.4877_4878delAA p.N1626fs fs del 50 serous 
case BRCA2 11 c.4965C>G p.Y1655* nonsense 62 serous 
case BRCA2 11 c.5073dupA p.K1691fs fs ins 49 serous 
case BRCA2 11 c.5213_5216delCTTA p.T1738fs fs del 42 serous 
case BRCA2 11 c.5238dupT p.S1746fs fs ins 54 serous 
case BRCA2 11 c.5290_5291delTC p.S1764fs fs del 58 serous 
case BRCA2 11 c.5304_5305delTT p.L1768fs fs del 54 serous 
case BRCA2 11 c.5351_5352delAA p.N1784fs fs del 64 serous 
case BRCA2 11 c.5351_5352delAA p.N1784fs fs del 56 serous 
case BRCA2 11 c.5351_5352delAA p.N1784fs fs del 58 clear cell 
case BRCA2 11 c.5351_5352delAA p.N1784fs fs del 57 serous 
case BRCA2 11 c.5576_5579delTTAA p.I1859fs fs del 65 serous 
case BRCA2 11 c.5682C>G p.Y1894* nonsense 49 clear cell 
case BRCA2 11 c.5864C>A p.S1955* nonsense 71 serous 
case BRCA2 11 c.5909C>A p.S1970* nonsense 56 serous 
case BRCA2 11 c.5909C>A p.S1970* nonsense 52 serous 
case BRCA2 11 c.5909C>A p.S1970* nonsense 51 undifferentiated 
case BRCA2 11 c.6037A>T p.K2013* nonsense 68 serous 
case BRCA2 11 c.6052_6053delAG p.S2018fs fs del 62 serous 
case BRCA2 11 c.6079dupA p.R2027fs fs ins 50 serous 
case BRCA2 11 c.6276_6277delTT p.L2092fs fs del 43 serous 
case BRCA2 11 c.6276_6277delTT p.L2092fs fs del 54 serous 
case BRCA2 11 c.6276_6277delTT p.L2092fs fs del 60 serous 
case BRCA2 11 c.6276_6277delTT p.L2092fs fs del 74 serous 
case BRCA2 11 c.6624delT p.N2208fs fs del 58 undifferentiated 
case BRCA2 11 c.6719delT p.L2240fs fs del 49 serous 
case BRCA2 11 c.6815_6816delGA p.R2272fs fs del 42 mucinous 
case BRCA2 14 c.7069_7070delCT p.L2357fs fs del 68 undifferentiated 
case BRCA2 14 c.7069_7070delCT p.L2357fs fs del 69 serous 
case BRCA2 14 c.7069_7070delCT p.L2357fs fs del 65 other 
case BRCA2 14 c.7069_7070delCT p.L2357fs fs del 57 serous 
case BRCA2 14 c.7069_7070delCT p.L2357fs fs del 65 serous 
case BRCA2 14 c.7069_7070delCT p.L2357fs fs del 60 serous 
case BRCA2 14 c.7312delG p.D2438fs fs del 48 endometrioid 
case BRCA2 14 c.7425delA p.E2475fs fs del 64 serous 
case BRCA2 15 c.7480C>T p.R2494* nonsense 64 serous 
case BRCA2 15 c.7566_7567delTC p.S2522fs fs del 57 undifferentiated 
case BRCA2 16 c.7762delA p.I2588fs fs del 59 serous 
case BRCA2 16 c.7762delA p.I2588fs fs del 50 serous 
case BRCA2 17 c.7934delG p.R2645fs fs del 57 serous 
case BRCA2 I_17 c.7976+5G>C - splicing 59 serous 
case BRCA2 I_18 c.8331+2T>C - splicing 59 serous 
case BRCA2 21 c.8633_8634delAA p.E2878fs fs del 50 serous 
case BRCA2 21 c.8633_8634delAA p.E2878fs fs del 54 undifferentiated 
case BRCA2 24 c.9196C>T p.Q3066* nonsense 48 serous 
case BRCA2 25 c.9294C>G p.Y3098* nonsense 56 serous 
case BRCA2 25 c.9294C>G p.Y3098* nonsense 61 serous 
case BRCA2 25 c.9382C>T p.R3128* nonsense 59 endometrioid 
case BRCA2 25 c.9434_9435delTG p.V3145fs fs del 51 mixed cell 
case BRCA2 27 c.10107dupT p.T3369fs fs ins 62 serous 
case MLH1 12 c.1333C>T p.Q445* nonsense 82 clear cell 
case MSH2 I_11 c.1759+1G>A - splicing 46 clear cell 
case MSH2 I_12 c.2006-5T>A - splicing 73 serous 
case MSH6 3 c.467C>G p.S156* nonsense 70 serous 
case MSH6 4 c.2150_2153delTCAG p.V717fs fs del 49 undifferentiated 
case MSH6 4 c.2194C>T p.R732* nonsense 43 clear cell 
case MSH6 4 c.2680C>T p.Q894* nonsense 43 undifferentiated 
case MSH6 4 c.2731C>T p.R911* nonsense 47 undifferentiated 
case MSH6 4 c.2736G>A p.W912* nonsense 43 mucinous 
case MSH6 4 c.3103C>T p.R1035* nonsense 56 clear cell 
case MSH6 4 c.642C>G p.Y214* nonsense 54 endometrioid 
case MSH6 6 c.3514dupA p.R1172fs fs ins 58 clear cell 
case MSH6 8 c.3758dupT p.V1253fs fs ins 54 endometrioid 
case PMS2 11 c.1831dupA p.I611fs fs ins 53 endometrioid 
 a fs del: frameshift deletion; fs ins: frameshift insertion.  b refage: interview age for control and diagnosis 
age for case. Accession number as follow: BRCA1, NM_007294; BRCA2, NM_000059; MLH1, 
NM_000249; MSH2, NM_000251, MSH6, NM_000179; PMS2, NM_000535. 
Supplementary Table S2: Catalogue of deleterious missense/synonymous 
variants found in the study 
status gene exon cDNA protein refage Morphology 
Mutation 
type reference
case BRCA1 2 c.1A>G p.M1V 67 serous missense 1 
case BRCA1 5 c.181T>G p.C61G 43 serous missense 2 
case BRCA1 5 c.181T>G p.C61G 43 serous missense 2 
case BRCA1 5 c.181T>G p.C61G 44 serous missense 2 
case BRCA1 15 c.4675G>A* p.E1559K 41 serous missense 3 
case BRCA1 18 c.5095C>T p.R1699W 50 serous missense 4 
case BRCA1 18 c.5096G>A p.R1699Q 69 serous missense 5 
case BRCA1 18 c.5096G>A p.R1699Q 61 serous missense 5 
case BRCA1 18 c.5096G>A p.R1699Q 66 serous missense 5 
case BRCA1 18 c.5096G>A p.R1699Q 61 serous missense 5 
case BRCA1 20 c.5213G>A p.G1738E 61 serous missense 4 
case BRCA2 18 c.8167G>C p.D2723H 63 serous missense 6 
case BRCA2 24 c.9154C>T p.R3052W 68 serous missense 7 
case BRCA2 24 c.9154C>T p.R3052W 67 serous missense 7 
case MLH1 17 c.1961C>T p.P654L 56 endometrioid missense 8 
case MSH2 7 c.1275A>G* p.E425E 65 serous synonymous 8 
case MSH2 7 c.1275A>G* p.E425E 68 endometrioid synonymous 8 
control MSH6 9 c.4001G>A* p.R1334Q 32 NA missense 8 
control MSH6 4 c.1346T>C p.L449P 32 NA missense 8 
* variants predicted by MaxEntScan to affect splicing. Accession number as follow: BRCA1, NM_007294; 
BRCA2, NM_000059; MLH1, NM_000249; MSH2, NM_000251, MSH6, NM_000179; PMS2, 
NM_000535. 
References of evidence of potential functional missense variants: 
   1.  Walsh,T., Casadei,S., Lee,M.K., Pennil,C.C., Nord,A.S., Thornton,A.M., Roeb,W., 
Agnew,K.J., Stray,S.M., Wickramanayake,A., et al. (2011) Mutations in 12 genes for 
inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively 
parallel sequencing. Proc. Natl Acad. Sci. USA, 108, 18032-18037. 
 2.  Kaufman,B., Laitman,Y., Gronwald,J., Lubinski,J., Friedman,E. (2009) Haplotype of 
the C61G BRCA1 mutation in Polish and Jewish individuals. Genet. Test. Mol. 
Biomarkers, 13, 465-469. 
 3.  Wappenschmidt,B., Becker,A.A., Hauke,J., Weber,U., Engert,S., Kohler,J., Kast,K., 
Arnold,N., Rhiem,K., Hahnen,E., et al. (2012) Analysis of 30 putative BRCA1 splicing 
mutations in hereditary breast and ovarian cancer families identifies exonic splice site 
mutations that escape in silico prediction. PLoS One, 7, e50800. 
 4.  Carvalho,M.A., Marsillac,S.M., Karchin,R., Manoukian,S., Grist,S., Swaby,R.F., 
Urmenyi,T.P., Rondinelli,E., Silva,R., Gayol,L., et al. (2007) Determination of cancer 
risk associated with germ line BRCA1 missense variants by functional analysis. Cancer 
Res., 67, 1494-1501. 
 5.  Spurdle,A.B., Whiley,P.J., Thompson,B., Feng,B., Healey,S., Brown,M.A., 
Pettigrew,C., van Asperen,C.J., Ausems,M.G., Kattentidt-Mouravieva,A.A., et al. 
(2012) BRCA1 R1699Q variant displaying ambiguous functional abrogation confers 
intermediate breast and ovarian cancer risk. J. Med. Genet., 49, 525-532. 
 6.  Chenevix-Trench,G., Healey,S., Lakhani,S., Waring,P., Cummings,M., Brinkworth,R., 
Deffenbaugh,A.M., Burbidge,L.A., Pruss,D., Judkins,T., et al. (2006) Genetic and 
histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown 
clinical significance. Cancer Res., 66, 2019-2027. 
 7.  Mohammadi,L., Vreeswijk,M.P., Oldenburg,R., van den Ouweland,A., Oosterwijk,J.C., 
van der Hout,A.H., Hoogerbrugge,N., Ligtenberg,M., Ausems,M.G., van der Luijt,R.B., 
et al. (2009) A simple method for co-segregation analysis to evaluate the pathogenicity 
of unclassified variants; BRCA1 and BRCA2 as an example. BMC Cancer, 9, 211. 
   8.  Thompson,B.A., Spurdle,A.B., Plazzer,J.P., Greenblatt,M.S., Akagi,K., Al-Mulla,F., 
Bapat,B., Bernstein,I., Capella,G., den Dunnen,J.T., et al. (2013) Application of a 5-
tiered scheme for standardized classification of 2,360 unique mismatch repair gene 
variants in the InSiGHT locus-specific database. Nat. Genet. doi: 10.1038/ng.2854 
 
 
 
Supplementary Table S3:  Sequencing coverage by gene   
 
Gene 
 
Accession 
number 
No. of 
coding 
exons 
Total 
coding 
length 
(bp)* 
No. of 
amplicons 
designed 
 coding 
sequence* 
covered by 
design (%) 
sequence 
read 
depth>15 
(%) 
 sequence 
read 
depth>30 
(%) 
BRCA1 NM_007294 22 6138 64 96 92 91 
BRCA2 NM_000059 26 10907 118 95 84 83 
MLH1 NM_000249 19 2739 35 97 88 87 
MSH2 NM_000251 16 3195 38 94 82 80 
MSH6 NM_000179 10 4317 50 96 79 79 
PMS2 NM_000535 15 2953 33 94 71 69 
* The sequence also contains 20 bp in the intron for 3’ acceptor sites and 6 bp in the intron for 
the donor 5’ sites. 
Supplementary Table 4: Comparison of deleterious BRCA1/BRCA2 variants 
detected in SEARCH, MAYO and the two largest published studies1, 2 
Mutation type SEARCH %* 
Mayo 
Clinic % * CAN1 %* AUS2 %* 
Large rearrangement 0 0 0 0 14 1 8 1 
BRCA1.185delAG (c.66_67delAG) 0 0 0 0 10 1 4 0 
BRCA1.5382insC(c.5266dupC) 2 0 3 0 11 1 8 1 
BRCA2.6174delT 
(c.5946_5946delT) 0 0 0 0 3 0 3 0 
Other BRCA1/2 mutations 106 8 67 7 138 10 118 12 
Total BRCA1/2 mutations 108 8 70 8 176 13 141 14 
Total (high grade serous only) 63 14 59 9 135 18 98 23 
* 
 Percentage of mutation carriers for all cases in each study. 
1 
  Zhang,S. et al (2011) Frequencies of BRCA1 and BRCA2 mutations among 1,342   
     unselected patients with invasive ovarian cancer. Gynecol. Oncol, 121, 353-357. 
2    Alsop,K., et al. (2012) BRCA mutation frequency and patterns of treatment response in  
    BRCA mutation-positive women with ovarian cancer: a report from the Australian   
Ovarian Cancer Study Group. J Clin Oncol, 30, 2654-2663. 
 
Supplementary Table 5: Comparison of clinical characteristics of cases in SEARCH, MAYO and the two largest published studies. 
  All cases (N and % of all cases)   BRCA1 and BRCA2 carriers (N and %  of each subgroup) 
  
SEARCH 
(N=1310) % 
Mayo clinic      
(N= 912) % 
CAN1 
(N=1342) % 
AUS2 
(N=1001) %  
SEARCH       
(N = 108) % 
Mayo clinic       
(N= 70) % 
CAN1 
(N=176) % 
AUS2 
(N=141) % 
Morphology                  
   Serous 600 46 677 
7
4 751 56 709 71  72 12 60 9 135 18 118 17 
   Clear Cell 137 10 55 6 91 7 63 6  3 2 3 5 2 2 4 6 
   Endometrioid 212 16 110 
1
2 287 21 119 12  11 5 2 2 26 9 10 8 
   Mucinous 132 10 25 3 112 8 0 0  1 1 1 4 0 0 0 0 
   Other/Unknown 229 17 45 5 101 8 110 11  18 8 4 9 13 13 9 8 
                  
Stage                  
   I 431 33 141 
1
5 NA  122 12  16 4 4 3 NA  8 7 
   II 121 9 51 6 NA  74 7  9 7 3 6 NA  9 12 
   III 368 28 538 
5
9 NA  566 57  45 12 43 8 NA  91 16 
   IV 66 5 171 
1
9 NA  113 11  9 14 20 12 NA  17 15 
   Unknown 324 25 11 1 NA  126 13  29 9 0 0 NA  16 13 
                  
Grade                  
   Low grade (I) 169 13 128 
1
4 NA  50 5  4 2 2 2 NA  2 4 
   High grade (II/III) 714 55 754 
8
3 NA  735 73  79 11 67 9 NA  113 15 
   Unknown 427 33 30 3 NA  216 22  25 6 1 3 NA  26 12 
                  
Family history                  
   Ovarian cancer 67 5 39 4 79 6 NA   20 30 9 23 36 46 NA  
   Breast cancer 165 13 155 
1
7 248 18 NA   23 14 32 21 75 30 NA  
   Ovarian/breast cancer 224 17 184 
2
0   194 19  42 19 36 20   75 39 
   No Family history 805 61 649 
7
1 993 74 749 75  40 5 30 5 78 8 62 8 
   Unknown 281 21 79 9 50 4 58 6  26 9 4 5     
                  
Age at diagnosis, years                 
  <40 72 5 28 3 82 6 45 4  4 6 2 7 9 11 7 16 
  40-49 239 18 97 
1
1 283 21 153 15  28 12 17 18 68 24 37 24 
  50-59 489 37 235 
2
6 392 29 346 35  46 9 24 10 51 13 59 17 
 >=60 510 39 552 
6
1 574 43 457 46   30 6 27 5 48 8 38 8 
       1.  Zhang,S., et al. (2011) Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol. Oncol, 121, 
353-357. 
       2.  Alsop,K., et al. (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report 
from the Australian Ovarian Cancer Study Group. J Clin Oncol, 30, 2654-2663. 
 
